6 results about "Immunologic Procedures" patented technology

Provided are a Trichinella spiralis vaccine kit based on a prime-boost sequential immunization program and use thereof, improving the protective effect against trichinosis. The kit is divided into two parts; the first part is a Trichinella spiralis recombinant protein vaccine having an amino acid sequence set forth in SEQ ID NO. 1 or SEQ ID NO. 2, and the second part is a recombinant adenovirus expressing an amino acid sequence set forth in SEQ ID NO. 1. The prime-boost immunization strategy not only effectively avoids the deficiency associated with a single-type Trichinella spiralis vaccine, but also significantly improves the efficacy and durability of the immune response.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

Provided are a rabies virus G protein mutant, a preparation method and application thereof, and relate to the technical field of biological medicine. The rabies virus G protein mutant is obtained by point mutation on the extracellular domain of the G protein. The mutant realizes soluble expression of the extracellular domain of the G protein, and can induce production of high-titer neutralizing antibodies. Compared with commercial human rabies vaccine and canine rabies vaccine, the mutant has more excellent cellular immune and antibody immune responses, and is expected to reduce the number of inoculations, shorten the immunization program and reduce the immunization dose.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The invention belongs to the field of immunology, and particularly relates to a method for constructing an animal model and application thereof. The method comprises the following steps: firstly, providing a method for constructing a mouse model, namely constructing four transgenic mice by using artificial chromosomes, two different DNA recombinase and three different reporter genes, and mating to obtain the transgenic mice carrying the three different reporter genes at the same time, the mouse can be used for tracking Th1 cell differentiation and central memory T cell development in an animal body. The invention also provides a method for evaluating the immune efficacy of the vaccine, which comprises the following steps: immunizing a mouse according to an immune procedure and a dose capable of causing immune response, extracting lymphocytes of the mouse, performing flow cytometry staining, and observing a result. Through a constructed mouse model, it is found that differentiated Th1 type effector cells capable of stably expressing T-bet can be developed into CCR7 + CD4 + TCM cells, and analysis of functions and development differentiation of the cells can provide a new thought for development of cellular immune vaccines with higher effector functions and long protection periods.

The application provides a kind of preventive inoculation information quick entry and check device, relating to medical information technology field, including information collection registration module, database storage module, central check processing module, interactive alarm module and inoculation execution confirmation module;The application obtains the identity of the recipient and vaccine information through multi-modal mode, and encapsulates into standardized data packet, avoids the problem of low efficiency of manual entry, then the central check processing module carries out real-time, multi-dimensional logical reasoning calculation based on dynamic rules, and the back-end operation and management indexes such as cold chain quality and inventory status are preposed as real-time check dimensions as important as medical contraindications and immunization programs, so that the use of invalid vaccine, inventory shortage misregistration and other difficult to prevent risks are actively intercepted before inoculation occurs, and further, the man-machine collaborative decision mechanism of alarm state is introduced, which ensures that the safety bottom line is not broken, and gives the final decision-making right to medical staff in complex situation.